Single-center, Open-label Study With 14C-radiolabeled ACT-246475 to Investigate Its Mass Balance, Pharmacokinetics, and Metabolism Following Single Subcutaneous Administration to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Selatogrel (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease; Myocardial infarction
- Focus Pharmacokinetics
- Sponsors Idorsia Pharmaceuticals
- 09 Oct 2018 Status changed from recruiting to completed.
- 07 Sep 2018 Status changed from not yet recruiting to recruiting.
- 25 Jul 2018 New trial record